Potential synaptic plasticity‐based Shenzhiling oral liquid for a SAD Mouse Model

BACKGROUND: Synaptic plasticity is the basis of memory formation. The pathological manifestations of abnormal glucose metabolism in the nervous system of sporadic Alzheimer's disease (SAD) may affect synaptic plasticity, thus causing memory damage. As a traditional Chinese medicine compound preparation, the mechanism by which Shenzhiling (SZL) oral liquid can alleviate the cognitive impairment of SAD by improving synaptic plasticity remains unclear. Objective: This article mainly discusses whether SZL can exert a protective synaptic effect as mediated by glutamate receptors and glycogen synthesis kinase 3β (GSK3β); further, it discusses whether SZL can improve cognitive function in SAD. METHODS: C57BL/6 mice were used as a SAD model after injection with streptozotocin (STZ) into the bilateral lateral ventricles; mice of the same background were injected with artificial cerebrospinal fluid into bilateral ventricles and were used as a control group. After 3 months of exposure to the intervention, the step‐down test was carried out. Western blot was used to detect the levels of NMDAR2B, p‐NMDAR2B, mGlu5, GSK3β, and p‐GSK3β in the hippocampus of mice. Immunohistochemical analysis was used to observe the number of GSK3β‐positive cells in the CA1 region of mouse hippocampus. RESULTS: The memory retention ability of mice was significantly improved after 3 months of SZL treatment, and the expression levels of NMDAR2B, mGlu5, and GSK3β were significantly changed. CONCLUSION: Shenzhiling provides a potential for the treatment for SAD with traditional Chinese medicine.